Movement disorders:湘雅医院:狗狗嗅一嗅,就能诊断帕金森病?

2022-08-29 Freeman MedSci原创

使用嗅探犬进行测试可能是一种有用的、无创的、快速的和具有成本效益的方法

帕金森病(PD)的诊断可以通过死后的病理检查很好地确定。然而,对于临床医生来说,在许多情况下做出正确的死前诊断仍然是一个巨大的挑战。与病理检查相比,总体准确率为81%。PD诊断的最新标准仍然很复杂,这对非运动障碍专家来说尤其是个问题。

图1: 论文封面图

在许多情况下,对临床上确立的PD进行诊断的时间往往需要数年。需要一种测试来确定PD的诊断,并提高准确性和可重复性。Trivedi及其同事报告说,"超级嗅探者 "可以仅通过气味识别PD,并确定了几种化合物,这些化合物在混合后可以被 "超级嗅探者 "识别为代表PD患者的气味。

长期以来,狗一直被用来搜索非法毒品、爆炸物和失踪人员。最近,越来越多的报告支持狗检测医疗状况的能力,如癌症、疟疾,以及最近的2019年冠状病毒疾病。这些报告表明,嗅探犬可能具有通过嗅觉识别PD的潜力。

因此,湘雅医院的Chang-Qing Gao等人,评估了嗅探犬区分PD患者和非PD对象的能力。


他们在中国的四个三级医疗中心进行了一项前瞻性、诊断性的病例对照研究,评估嗅探犬区分109名临床确定的药物治疗PD患者、654名无PD的受试者、37名药物治疗PD患者和185名非PD对照者的准确性。主要结果是嗅探犬识别的灵敏度和特异度。

他们发现:在对用药患者的研究中,当两只或全部三只嗅探犬在测试的样本中产生阳性检测结果时,指数测试的敏感性、特异性以及阳性和阴性似然比分别为91%(95%CI:84%-96%)、95%(95%CI:93%-97%),以及19.16(95%CI:13.52-27.16)和0.10(95%CI:0.05-0.17)。

 

图2:论文结果图

在未用药的患者中,相应的敏感性、特异性、阳性和阴性似然比分别为89%(95%CI:75%-96%)、86%(95%CI:81%-91%),以及6.6(95%CI:4.51-9.66)和0.13(95%CI:0.05-0.32)。

该研究的重要意义在于发现了:使用嗅探犬进行测试可能是一种有用的、无创的、快速的和具有成本效益的方法,可以在社区筛查和健康预防检查以及神经科实践中识别PD患者。

 

原文出处:
Gao C, Wang S, Wang M, et al. Sensitivity of Sniffer Dogs for a Diagnosis of Parkinson’s Disease: A Diagnostic Accuracy Study. _Movement Disorders_. Published online August 25, 2022:mds.29180. doi:[10.1002/mds.29180](https://doi.org/10.1002/mds.29180)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1878574, encodeId=4fee18e85743c, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Nov 29 09:57:06 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077719, encodeId=c64720e7719de, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Wed Nov 30 10:57:06 CST 2022, time=2022-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013949, encodeId=64bf20139494d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 20 09:57:06 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784540, encodeId=01441e84540ca, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Jun 03 14:57:06 CST 2023, time=2023-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738151, encodeId=3bcd1e381516b, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Mon Mar 06 03:57:06 CST 2023, time=2023-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595818, encodeId=098215958185c, content=<a href='/topic/show?id=d39e6642328' target=_blank style='color:#2F92EE;'>#湘雅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66423, encryptionId=d39e6642328, topicName=湘雅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=853618305022, createdName=xiaoshitou, createdTime=Tue Aug 30 12:57:06 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
    2022-11-29 anminleiryan
  2. [GetPortalCommentsPageByObjectIdResponse(id=1878574, encodeId=4fee18e85743c, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Nov 29 09:57:06 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077719, encodeId=c64720e7719de, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Wed Nov 30 10:57:06 CST 2022, time=2022-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013949, encodeId=64bf20139494d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 20 09:57:06 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784540, encodeId=01441e84540ca, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Jun 03 14:57:06 CST 2023, time=2023-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738151, encodeId=3bcd1e381516b, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Mon Mar 06 03:57:06 CST 2023, time=2023-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595818, encodeId=098215958185c, content=<a href='/topic/show?id=d39e6642328' target=_blank style='color:#2F92EE;'>#湘雅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66423, encryptionId=d39e6642328, topicName=湘雅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=853618305022, createdName=xiaoshitou, createdTime=Tue Aug 30 12:57:06 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1878574, encodeId=4fee18e85743c, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Nov 29 09:57:06 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077719, encodeId=c64720e7719de, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Wed Nov 30 10:57:06 CST 2022, time=2022-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013949, encodeId=64bf20139494d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 20 09:57:06 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784540, encodeId=01441e84540ca, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Jun 03 14:57:06 CST 2023, time=2023-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738151, encodeId=3bcd1e381516b, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Mon Mar 06 03:57:06 CST 2023, time=2023-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595818, encodeId=098215958185c, content=<a href='/topic/show?id=d39e6642328' target=_blank style='color:#2F92EE;'>#湘雅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66423, encryptionId=d39e6642328, topicName=湘雅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=853618305022, createdName=xiaoshitou, createdTime=Tue Aug 30 12:57:06 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1878574, encodeId=4fee18e85743c, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Nov 29 09:57:06 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077719, encodeId=c64720e7719de, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Wed Nov 30 10:57:06 CST 2022, time=2022-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013949, encodeId=64bf20139494d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 20 09:57:06 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784540, encodeId=01441e84540ca, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Jun 03 14:57:06 CST 2023, time=2023-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738151, encodeId=3bcd1e381516b, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Mon Mar 06 03:57:06 CST 2023, time=2023-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595818, encodeId=098215958185c, content=<a href='/topic/show?id=d39e6642328' target=_blank style='color:#2F92EE;'>#湘雅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66423, encryptionId=d39e6642328, topicName=湘雅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=853618305022, createdName=xiaoshitou, createdTime=Tue Aug 30 12:57:06 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
    2023-06-03 cmsvly
  5. [GetPortalCommentsPageByObjectIdResponse(id=1878574, encodeId=4fee18e85743c, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Nov 29 09:57:06 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077719, encodeId=c64720e7719de, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Wed Nov 30 10:57:06 CST 2022, time=2022-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013949, encodeId=64bf20139494d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 20 09:57:06 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784540, encodeId=01441e84540ca, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Jun 03 14:57:06 CST 2023, time=2023-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738151, encodeId=3bcd1e381516b, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Mon Mar 06 03:57:06 CST 2023, time=2023-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595818, encodeId=098215958185c, content=<a href='/topic/show?id=d39e6642328' target=_blank style='color:#2F92EE;'>#湘雅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66423, encryptionId=d39e6642328, topicName=湘雅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=853618305022, createdName=xiaoshitou, createdTime=Tue Aug 30 12:57:06 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1878574, encodeId=4fee18e85743c, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Nov 29 09:57:06 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077719, encodeId=c64720e7719de, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Wed Nov 30 10:57:06 CST 2022, time=2022-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013949, encodeId=64bf20139494d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 20 09:57:06 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784540, encodeId=01441e84540ca, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Jun 03 14:57:06 CST 2023, time=2023-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738151, encodeId=3bcd1e381516b, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Mon Mar 06 03:57:06 CST 2023, time=2023-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595818, encodeId=098215958185c, content=<a href='/topic/show?id=d39e6642328' target=_blank style='color:#2F92EE;'>#湘雅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66423, encryptionId=d39e6642328, topicName=湘雅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=853618305022, createdName=xiaoshitou, createdTime=Tue Aug 30 12:57:06 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
    2022-08-30 xiaoshitou

相关资讯

Movement disorders:血清MicroRNAs可预测孤立的快速眼动睡眠行为障碍和路易体疾病

仅特定的miRNA生物特征就有希望作为IRBD患者的进展生物标志物来预测PD和DLB的临床结果。

Movement disorders:大脑代谢与前驱和早期帕金森病中的多巴胺能失调有关

在前驱期和早期PD阶段,与多巴胺能神经支配有关的各个脑区的代谢反应的轨迹是不同的。

Science:GPNMB可能是帕金森病的重要的生物标志物

研究人员报告说,基于计算、细胞生物学和人体组织的研究将 GPNMB 确定为帕金森病 (PD) 的风险基因和潜在治疗靶点。 PD 是一种使人衰弱的进行性神经退行性脑部疾病,影响着全世界数百万人。 疾病的

JAMA Netw Open:做好这两点,帕金森病患者全因死亡风险骤降65%!

 JAMA Netw Open:饮食和身体活动与帕金森病成人全因死亡率的关系

JAMA子刊:高翔教授发现吃得对会运动,帕金森死亡率能降一半!

无论是健康饮食还是积极锻炼,都能充分保护帕金森患者的寿命。

Phytomedicine:地黄饮通过减轻外周炎症保护帕金森病模型多巴胺能神经元

验证中药配方地黄饮(DHY)对帕金森病(PD)小鼠模型的治疗作用,并探讨其潜在的分子机制。

拓展阅读

AAN 2024大会盛况回顾,带您领略神经病学新高度!

作为神经科医生,您一定对AAN 2024年大会充满期待。我们为您精心整理了大会内容解读,包括最新研究成果、临床实践经验和未来发展趋势等,让您足不出户就能领略到大会的精彩盛况!点击立即查看别错过!

AAN 2024:突触核蛋白皮肤活检在帕金森病的初步诊断的临床实践

帕金森病早期准确诊断是一项尚未满足的重大需求,这对于早期干预和预后改善有着重要的影响。

Nature Medicine:重塑帕金森病治疗前景:Prasinezumab在早期帕金森病快速进展亚型中的疗效分析

文章探讨了Prasinezumab这种单克隆抗体在早期帕金森病中的潜在的治疗作用。

【帕金森病专题分享】探索帕金森病进展及诊疗全攻略

帕金森病日来临之际,我们特别推出了帕金森病专题系列文章。无论你是初入此领域的新手,还是经验丰富的专家,这里都有你需要的知识和信息。点击立即阅读,共同提升帕金森病诊疗水平!

话题:帕金森病的真相你了解多少?

我们欢迎各位老师,学者们在下方评论区共同探讨帕金森病的各个方面,包括但不限于:帕金森病的介绍、早期症状、体征、预防等都可一起分享出来。

好文推荐 | 帕金森病睡眠障碍结构特征及其影响因素的临床研究

探讨帕金森病(PD)患者睡眠障碍的发生率、睡眠结构特征、影响因素。

2024 NICE 诊断指南:帕金森病远程监测设备 [DG51]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2024-01-25

2023 NICE 技术鉴定指南:左旋多巴/卡比多巴组合治疗伴有运动症状的晚期帕金森病[TA934]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2023-11-29

帕金森病患者睡眠障碍评估与护理干预的最佳证据总结

浙江中医药大学护理学院 · 2023-08-10

早中期帕金森病患者运动管理的最佳证据总结

山东第一医科大学附属省立医院老年神经内科 · 2023-05-10